相关实验视频

Updated: May 6, 2026

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

评估个人对抗PD-1治疗的个性化反应,使用患者衍生肺瘤芯片

Irina Veith¹, Martin Nurmik², Arianna Mencattini³

¹Institut Curie, INSERM U830, Stress and Cancer Laboratory, PSL Research University, 26 rue d'Ulm, 75005 Paris, France; Institut Roche, 30 Cours de l'Île Seguin, 92100 Boulogne-Billancourt, France.

Cell reports. Medicine

|May 4, 2024

概括

肺瘤芯片平台预测免疫疗法药物疗效. 这些模型结合了患者细胞和树皮元素来评估T细胞反应和免疫疗法耐药性,为临床使用铺平了道路.

科学领域:

在瘤学瘤学.
生物技术是生物技术.
微流体学微流体学

背景情况:

预测免疫疗法药物疗效对于癌症治疗至关重要.
瘤芯片技术使用微流体技术创建3D瘤模型.
这些模型模仿了用于药物测试的简化瘤生态系统.

研究的目的:

开发和验证肺瘤在芯片上的平台.
精确测量ex vivo T 细胞介导的癌细胞死亡.
评估 stromal 相互作用对免疫治疗反应的影响.

主要方法:

利用微流体技术在水凝中生成3D共培养.
综合自主癌症相关纤维细胞 (CAFs).
采用实时成像和先进的图像分析来监测T细胞活动.

主要成果:

证明T细胞介导的癌细胞死亡测量实体.
表明免疫抑制性CAFs损害了抗PD-1反应.
经过验证的瘤芯片平台在回顾肌体依赖性免疫疗法耐药性.

结论:

瘤芯片技术有效地模拟了免疫疗法耐药性机制.
从患者样本上可以生成个性化的瘤芯片平台.
这项技术显示出未来在免疫瘤学中临床验证的潜力.

关键词:

这是一种抗PD-1药物.癌症模型癌症模型与癌症相关的纤维细胞.免疫瘤学免疫瘤学免疫疗法免疫疗法肺癌是一种肺癌.微流体学在微流体学方面患者衍生的患者衍生.瘤微环境是一个微环境.在芯片上的瘤

更多相关视频

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...